RHYTHM PHARMACEUTICALS, INC.

Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases. The company's primary asset is IMCIVREE (setmelanotide), a melanocortin-4 receptor agonist approved for treating obesity caused by genetic deficiencies in specific metabolic pathways. The drug targets rare genetic forms of obesity linked to POMC, LEPR, and other MC4R pathway defects, including Bardet-Biedl syndrome and Alström syndrome. The company is conducting Phase 3 clinical trials to expand IMCIVREE's indication to additional rare obesity subtypes, including SH2B1 deficiency and steroid receptor coactivator 1 deficiency obesity.

Rhythm maintains a partnership ecosystem through licensing agreements with international pharmaceutical companies including LG Chem Ltd., Ipsen Pharma S.A.S., and Camurus, as well as a joint research collaboration with Axovia Therapeutics focused on Bardet-Biedl syndrome. These partnerships support geographic expansion and development efforts across multiple markets.

The company operates with approximately 283 full-time employees and maintains headquarters in Boston, Massachusetts. Founded in 2008 and incorporated in Delaware, Rhythm was formerly known as Rhythm Metabolic, Inc. before rebranding in October 2015.